Orale Antikoagulanzien vom Cumarintyp

Zusammenfassung

Es wird ein Überblick über Pharmakologie und Indikationen zur Therapie mit Vitamin-K-Antagonisten gegeben sowie zur Therapiehandhabung mit Selbstkontrolle durch die Patienten .

Summary

A survey is given on pharmacology and indications for the treatment with vitamin K antagonists. The therapeutic handling and self control by the patient is described.

Schlüsselwörter

Vitamin-K-Antagonisten - Cumarinderivate - Thrombo - embolie - Antikoagulanzien-Selbstkontrolle

Keywords

Vitamin K antagonists - cumarine derivatives - thromboembolism - self control of treatment with anticoagulants

• Literatur

• 1 Barthels M, Poliwoda H. Gerinnungsanalysen 5. Aufl. Stuttgart: Thieme; 1997
• 2 Bauer KA. Management of patients with hereditary defects predisponsing to thrombosis including pregnant women. Thromb. Haemost 1995; 74: 94.
• 3 DIN 58911.. Teil 1 Hämostaseologie. Kalibrierung von Meßverfahren. DIN-Taschenbuch 261. Hämostaseologie. Berlin: Beuth; 1996
• 4 Hirsh J. Guide to anticoagulant therapy, part 2: oral anticoagulants. Circulation 1994; 89: 1469.
• 5 Hirsh J. Oral anticoagulants: mechanisms of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108 (Suppl. 04) 231S.
• 6 Hull R, Delmore T, Genton E. et al. Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
• 7 Hull R, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 1982; 3016: 189.
• 8 Kaufman DW, Kelly JP, Rosenberg L. et al. Recent patterns of medication use in the ambulatory adult population of thr United States: The Slone Survey. JAMA 2002; 287: 337-344.
• 9 Kearon C, Ginsberg JS. Kovacs et al. Comparison of low-intensity warfarin therapy with conventional- intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
• 10 Kemkes-Matthes B, Matzdorff A, Heidt M. et al. Initialphase der oralen Antikoagulanzientherapie: Vergleich verschiedener Dosierungen von Warfarin und Phenprocoumon. Hämostaseologie 2002; 22: 87-91.
• 11 Lagerstedt CI, Fagher BO, Albrechtsson U. et al. Need for long term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 51.
• 12 Liebig S, Stracke H, Nees M, Kemkes-Matthes B. Osteoporose bei Patienten unter oraler Antikoagulantien- Therapie. Dtsch Med Wochenschr 2004; 129: 2707-2710.
• 13 Mannucci PM, Bottasso B, Tripodi A. et al. Prothrombin fragment 1+2 and intensity of treatment with oral anticoagulants. Thromb Haemost 1991; 66: 741.
• 14 Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-685.
• 15 Menéndez-Jándula B, Souto JC, Oliver A. et al. Comparing self-management of oral anticoagulant therapy with clinic management. Ann Intern Med 2005; 142: 1-10.
• 16 Mok CK, Boey J, Wang R. et al. Warfarin versus dipyridamole – aspirin and petoxyphylline – aspirin for the prevention of proshtetic heart valve thromboembolism: a prospective clinical trial. Circulation 1985; 72: 1059.
• 17 Müller-Beißenhirz W, Deickert F, Lang H. et al. Selbstkontrolle der oralen Antikoagulation: Standortbestimmung. Hämostaseologie 1998; 18: 84-88.
• 18 Oldenburg J, Quenzel E-M, Harbrecht U. et al. Missense mutations at Ala-10 in the factor IX propeptide: in insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-244.
• 19 Oldenburg J, Seidel H, Pötsch B, Watzka M. Neue Einsichten in die orale Antikoagulationstherapie mit Cumarinen. Hämostaseologie 2008; 28: 44-50.
• 20 Petersen D, Barthels M. Die artefiziell manipulierte Krankheit durch heimliche Einahme des oralen Antikoagulans Phenprocoumon: Untersuchung an 16 eigenen Fällen. Med Klin 1995; 90: 277.
• 21 Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost 2004; 2: 849-860.
• 22 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 22: 2285-2293.
• 23 Ridker PM, Goldhaber SZ, Danielson E. et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-1434.
• 24 Rombouts EK, Rosendahl FR, van der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007; 5: 2043-2048.
• 25 Sconce E, Khan T, Mason J. et al. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93: 872-875.
• 26 Sixty-Plus Reinfarction Study Group.. A doubleblind trial to esses long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980; 2: 989-994.
• 27 Smith P, Arnesen H, Holme I. The effect of Warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323: 147.
• 28 Turpie AG, Gent M, Laupacis A. at al. Aspirin and Warfarin after heart-valve replacement: a comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993; 329: 524.
• 29 Watzke HH, Forberg E, Scolba G. et al. A prospective controlled trial comparing weekly selftesting and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb Haemost 2000; 83: 661-665.
• 30 Wawrzynska L, Tomkowski WZ, Przedlacki J. et al. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003; 33: 64-67.
• 31 Witt I, Beeser H, Lang H, Müller-Beißenhirtz W. Thromboplastinzeit und INR: Standardisierung der Methode, Anwendung zur Kontrolle der oralen Antikoagulantientherapie und als Globaltest der plasmatischen Gerinnung – Standortbestimmung. J Lab Med 1996; 20: 443.